Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy Now?

Is VKTX a bully banal to buy? We came across a bullish thesis connected Viking Therapeutics, Inc. connected Charlie Evans’s Substack by Charlie Evans PhD. In this article, we volition summarize the bulls’ thesis connected VKTX. Viking Therapeutics, Inc.'s stock was trading astatine $35.53 arsenic of April 20th.

Photo from Iovance Biotherapeutics website

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses connected the improvement of caller therapies for metabolic and endocrine disorders. VKTX is positioning itself arsenic a perchance compelling subordinate successful the obesity and type-2 diabetes attraction landscape, driven by its pb asset, VK2735, a dual GLP-1/GIP receptor agonist.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

VK2735 has demonstrated strong efficacy successful the Phase 2 VENTURE trials, with subcutaneous dosing delivering up to 14.7% mean value nonaccomplishment implicit 13 weeks, outperforming first-generation GLP-1 therapies. While gastrointestinal broadside effects remain a challenge, a much gradual titration successful Phase 3 is expected to amended tolerability.

The oral formulation of VK2735 besides shows promise, with 12.2% value nonaccomplishment astatine the 120 mg dose, though precocious discontinuation rates item the request for optimized dosing. Viking is addressing this done a afloat enrolled Phase 1 attraction study, which aims to prolong value nonaccomplishment with little oregon little predominant dosing, offering aboriginal insights into semipermanent adherence, tolerability, and efficacy that could meaningfully differentiate VK2735 from competitors.

The Phase 3 VANQUISH programme is underway, with VANQUISH-1 afloat enrolled and VANQUISH-2 nearing completion. Data from these studies, on with the attraction trial, are expected successful 2026–2027, perchance supporting some subcutaneous and oral filings by 2028/2029. Viking is besides expanding its pipeline with a Dual Amylin and Calcitonin Receptor Agonist (DACRA), targeting patients incapable to tolerate GLP-1s, with IND submission planned for Q1 2026.

The company’s commercialized readiness is underscored by a seasoned enactment prosecute and a manufacturing statement susceptible of supporting multibillion-dollar production. With $706 cardinal successful currency and a de-risked proviso chain, Viking is well-capitalized to execute connected upcoming milestones. Collectively, VK2735’s competitory efficacy, emerging attraction strategy, oral formulation, and DACRA pipeline, combined with robust fiscal positioning, suggest VKTX could present important upside for speculative investors seeking vulnerability to the evolving obesity and GLP-1 therapeutic market.